ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Other Events

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Other Events
Item 8.01. Other Events

On May 22, 2017, Anthera Pharmaceuticals, Inc. (“Anthera”) completed an adjustment to the exercise price of certain warrants to purchase common stock (the “Warrants”) that were issued in connection with the previously announced $15.0 million underwritten public offering of Company common stock and Warrants that closed on March 17, 2017. The Warrants were sold in two tranches (the “Tranche 1 Warrants” and the “Tranche 2 Warrants”). Each Tranche 1 Warrant was initially issued with an exercise price of $0.55 per share of Company common stock and each Tranche 2 Warrant was issued with an exercise price of $0.50. In connection with the Company’s 1-for-8 reverse stock split that became effective at 5:00p.m. Eastern Time on April 28, 2017 (the “Reverse Stock Split”), the exercise price of the Tranche 1 Warrants and the Tranche 2 Warrants were adjusted to $4.50 and $4.00, respectively. to the terms of the Warrants, on May 22, 2017, the sixteenth trading day immediately following the Reverse Stock Split, the Company adjusted the exercise price of the Warrants to $1.8918, which was the volume weighted average price of the five lowest trading days during the fifteen consecutive trading days following the Reverse Stock Split.

About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session up +0.04 at 1.74 with 111,861 shares trading hands.

An ad to help with our costs